Today we welcome Dr. Daniel Vitt, CEO of Immunic Therapeutics.

With World MS Day being tomorrow, the 30th of May, this is the perfect moment to focus on multiple sclerosis — a disease that affects nearly three million people worldwide and still leaves many patients searching for better options.

In today’s episode Daniel shares his own journey into biotechnology, walk us through what life with MS really looks like for patients, and explain the science behind Immunic’s most advanced program, IMU-838. We discuss what makes Immunic’s oral therapy different from today’s treatments, uncover the latest data from the CALLIPER and ENSURE trials, and talk about what the future of MS care could look like.

• 01:22 Meet Daniel Vitt
• 04:54 Understanding multiple sclerosis
• 07:53 Evolution of the MS treatment landscape
• 12:08 Immunic’s lead MS therapy explained
• 22:57 World MS Day and what's next for Immunic

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

To dive deeper into the topic:

• 11 neuroscience biotech companies you should know about
• The emergence of BTK inhibitors in multiple sclerosis treatment: Companies close in on approval
• Six biotech companies advancing multiple sclerosis therapies